Search
HNM01
go.drugbank.com/drugs/DB06531ExperimentalIt entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase … The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.
Biapenem
go.drugbank.com/drugs/DB13028InvestigationalIt is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]
Chlorcyclizine
go.drugbank.com/drugs/DB08936ApprovedChlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms.
Mixtures: Notuss-NXPermethrin
go.drugbank.com/drugs/DB04930ApprovedInvestigationalIt is a yellow to light orange-brown, low melt-ing solid or viscous liquid.
Fosamprenavir
go.drugbank.com/drugs/DB01319ApprovedInvestigationalFosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
Aminophylline
go.drugbank.com/drugs/DB01223ApprovedInvestigationalThe majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply. … Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma, chronic bronchitis, and COPD.
Doxapram
go.drugbank.com/drugs/DB00561ApprovedInvestigationalVet approvedA central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
Chromium picolinate
go.drugbank.com/drugs/DB11255ApprovedChromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor [A27235].
Acalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigational[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib. … expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK.
Zanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigationalZanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2).
Synonyms: SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP